British American Tobacco (BATS.L) — Company Research

Last Updated: 14 September 2026

British American Tobacco sells cigarettes in about 175 markets and is trying, publicly and expensively, to replace that business with vapes, heated tobacco and nicotine pouches before regulation and falling volumes do the job for it. The financial picture is a slow-shrinking top line, very high margins, heavy debt and a dividend the company has raised for more than two decades. This report works through what the 2025 Annual Report, the half-year announcement of 30 July 2026 and the group's SEC filings actually say. Every balance-sheet and cash-flow figure here has been re-derived from British American Tobacco's own XBRL data filed with the US Securities and Exchange Commission. There are no analyst opinions, price targets or ratings in it.

1. Company Snapshot

Field	Value
Ticker / exchange	BATS.L — London Stock Exchange (ADS: BTI, NYSE; also listed on the Johannesburg Stock Exchange)
Sector	Consumer staples — tobacco and nicotine products
Share price	4,100p (12 September 2026)
Market cap	£88.3bn
Shares in issue	~2.15bn ordinary shares of 25p
Revenue (FY2025)	£25,610m, down 1.0% as reported and up 2.1% at constant currency
Reported profit from operations (FY2025)	£9,997m
Adjusted profit from operations (FY2025)	£11,572m, a 44.0% adjusted operating margin
Reported diluted EPS (FY2025)	349.1p
Adjusted diluted EPS (FY2025)	352.1p
Dividend per share (FY2025)	245.04p, up 2.0%, paid in four equal quarterly instalments of 61.26p
Adjusted net debt (31 December 2025)	£30,416m; adjusted net debt to adjusted EBITDA 2.48x
Smokeless share of revenue (FY2025)	18.2%, rising to 19.8% at H1 2026; ambition is 50% or more by 2035
Employees	47,797 at 31 December 2025
CEO / Leadership	Tadeu Marroco, Chief Executive; Dragos Constantinescu, Chief Financial Officer since 1 September 2026; Luc Jobin, Chairman
Headquarters	Globe House, 4 Temple Place, London

Live price action and technical levels for British American Tobacco are on the ChartsView Live Charts page.

2. The Bull and Bear Case

Bull Case

• Cash generation is the whole point: FY2025 net cash from operating activities was £6,342m even after a £2,560m Canadian litigation settlement payment, and H1 2026 operating cash flow rose 47.3% to £3,402m with cash conversion of 79.7%. The company expects roughly £50bn of cumulative free cash flow before dividends across 2024 to 2030, of which £14.2bn had been generated by the H1 2026 stage.
• New Categories are turning profitable: New Categories revenue reached £3,621m in FY2025 and grew 18.0% at constant currency in H1 2026 to £1,928m, with the category contribution margin improving by 3.3 percentage points to 13.8%. The loss-making phase of the transition is largely behind it.
• Dividend and buyback both funded: the FY2025 dividend of 245.04p was the latest step in a run of increases stretching back more than two decades, and a £1.3bn buyback for 2026 was confirmed as on track at the half year, following £1.1bn in 2025. Leverage is guided to land inside the 2.0–2.5x target range by year end.
• Guidance moved up, not down: at the H1 2026 results on 30 July 2026 management raised the adjusted diluted earnings-per-share growth guidance to the middle of its 5–8% range, while holding revenue and adjusted operating profit at the lower end of the medium-term algorithm.

Bear Case

• The top line is going backwards: revenue was £25,684m in FY2021 and £25,610m in FY2025 — effectively flat in nominal terms across four years, and well down in real terms. Global cigarette volumes fell about 4.6% in H1 2026.
• Illicit trade is eating the transition: unregulated disposable vapes and smuggled cigarettes take share from the legal products the company is investing in. In Australia, illicit product now accounts for roughly 80% of combustible volume, a market effectively lost to legal operators.
• Regulatory risk is existential, not incidental: proposed US menthol and nicotine-level rules, premarket tobacco product application approvals, flavour bans and excise increases all sit outside the company's control and can remove entire revenue lines. The business exists at the sufferance of regulators in every market it serves.
• Litigation keeps arriving: the Canadian settlement is being paid down, but a third UK High Court shareholder claim over historical North Korea sanctions disclosure was filed in September 2026, following two in February 2026. Legal exposure has been a recurring drag on reported profit.
• Currency translation is a persistent headwind: the gap between reported and constant-currency figures has been wide and consistently unfavourable — FY2025 revenue fell 1.0% as reported but rose 2.1% at constant currency, and reported diluted earnings per share fell 28.6% in H1 2026 while the adjusted constant-currency measure rose 5.9%.

3. Revenue Segments

British American Tobacco reports geographically but also discloses revenue by product category. The category split matters more for understanding the investment case, so it is shown first. Figures are for the year ended 31 December 2025.

Segment / category	% of revenue	What it is
Combustibles (£20,201m)	78.9%	Traditional cigarettes and roll-your-own tobacco, including Dunhill, Kent, Lucky Strike, Pall Mall, Rothmans, Newport and Camel in the United States. Declining in volume, defended through price.
New Categories (£3,621m)	14.1%	Vapour (Vuse), heated products (glo) and modern oral nicotine pouches (Velo). Revenue grew 7.0% at constant currency in FY2025 and category contribution rose 77.1% to £427m.
Traditional Oral (£1,043m)	4.1%	Moist snuff and snus, largely in the United States and Scandinavia. Combined with New Categories this is the "smokeless" total of 18.2% of FY2025 revenue.
Other (£745m)	2.9%	Cigars, contract manufacturing, wellbeing products such as Ryde functional shots, and other non-core revenue.

The group also reports three geographic regions. For FY2025 these were the United States at £11,534m, or 45.0% of revenue; Americas and Europe at £9,309m, or 36.3%; and Asia-Pacific, Middle East and Africa at £4,767m, or 18.6%. At H1 2026 the United States had grown to 47.5% of the total at constant currency. The United States is therefore both the largest revenue pool and the source of the greatest single regulatory risk.

4. Business Model and Moat

How it makes money. The economics are simple and unusually favourable. Tobacco is cheap to grow and process, brands command loyalty that verges on the absolute, and advertising is banned in most markets — which means incumbents cannot be outspent by new entrants. The result is an adjusted operating margin of 44.0% in FY2025 on revenue of £25,610m. Volume declines of a few per cent a year are routinely offset by price increases, so revenue holds roughly flat while profit per unit rises.

Unit economics of the transition. New Categories were loss-making for years because devices are sold at thin margin to seed consumable sales — pods, sticks and pouches. That model is now working: category contribution reached £427m in FY2025, up 77.1%, and the contribution margin improved to 13.8% at H1 2026. The consumer base reached 34.1 million at the end of FY2025 and 35.0 million at H1 2026, against a target of 50 million by 2030.

Where the moat is. Regulation is, paradoxically, the moat. Marketing restrictions, plain packaging, retail licensing and excise systems all raise the cost of building a new nicotine brand far above what a start-up can bear, which protects the incumbents' shelf space. The same regulation is also the primary threat, because a single rule change can delete a product line. The moat and the risk are the same thing viewed from opposite sides.

What breaks the model. Illicit trade sits outside all of that. Unregulated disposable vapes and smuggled cigarettes pay no excise, follow no marketing rules and face no age checks, so they undercut legal products on price and availability at the same time. Where enforcement fails — Australia being the clearest example, with illicit product at roughly 80% of combustible volume — the legal market simply collapses regardless of brand strength.

5. Financial Health

British American Tobacco reports in pounds sterling. Revenue is stated net of duty, excise and other taxes. The figures below come from the group's preliminary results announcements and have been cross-checked against its SEC XBRL filings (CIK 0001303523).

Fiscal Year	Revenue (£m)	YoY %	GAAP EPS	Adjusted EPS	Dividend/share	Long-term debt (YE)
FY2021	25,684	n/a	295.6p	329.0p	217.80p	£39,658m
FY2022	27,655	+7.7%	291.9p	371.4p	230.90p	£43,139m
FY2023	27,283	−1.3%	(646.6)p	375.6p	235.52p	£39,730m
FY2024	25,867	−5.2%	136.0p	362.5p	240.24p	£36,950m
FY2025	25,610	−1.0%	349.1p	352.1p	245.04p	£35,070m

Notes on the table above. The long-term debt column is total borrowings including lease liabilities at each year end, taken directly from the group's SEC XBRL data. Adjusted net debt, the company's own preferred measure, was £30,416m at 31 December 2025. Adjusted earnings per share for FY2021 to FY2024 are the constant-currency figures disclosed in the relevant announcements; FY2023 reported earnings per share was a loss because of a £27.6bn non-cash impairment of US combustible brands, and FY2024 reported profit absorbed a £6.2bn charge for the Canadian litigation settlement.

The pattern is clear enough. Reported earnings per share is close to useless as a trend indicator because it has been dominated by two enormous one-off items in three years. Adjusted earnings per share has drifted from 329.0p to 352.1p across five years — low single-digit growth — while the dividend rose from 217.80p to 245.04p and borrowings fell from £39,658m to £35,070m. The company has been paying down debt and paying out cash, not growing.

Quarter / Half	Revenue (£m)	Adjusted EPS	GAAP EPS
H1 2026	12,235	171.6p	145.3p
H2 2025 (derived)	13,541	196.6p	145.5p
H1 2025	12,069	155.5p	203.6p
FY2025 total	25,610	352.1p	349.1p

British American Tobacco reports half-yearly rather than quarterly, so there are no quarterly figures to show. The H2 2025 row is derived by subtracting the disclosed H1 2025 figures from the disclosed FY2025 totals; it is arithmetic on published numbers, not a separately reported period.

Cash flow and balance sheet, all re-derived from SEC XBRL for the year ended 31 December 2025: net cash from operating activities £6,342m; purchases of property, plant and equipment £551m; depreciation, amortisation and impairment £2,547m, of which amortisation of intangibles other than goodwill was £1,724m and depreciation of property, plant and equipment including right-of-use assets was £521m; total borrowings £35,070m, of which short-term borrowings £3,362m; cash and cash equivalents £3,827m; total equity attributable to owners £46,033m. At 30 June 2026 borrowings were £35,063m and adjusted net debt £31,969m.

6. Valuation Metrics

Raw metrics, September 2026. Not opinions on whether the stock is cheap or expensive.

Metric	Value
Market cap	£88.3bn (4,100p × ~2.153bn shares, 12 September 2026)
Enterprise value	~£119.5bn (market cap £88.3bn + total borrowings £35.07bn − cash and cash equivalents £3.83bn, both per the 31 December 2025 balance sheet in the group's SEC XBRL data)
Trailing P/E (GAAP)	~14.1x (4,100p / trailing twelve-month reported diluted EPS of ~291p, being FY2025 349.1p less H1 2025 203.6p plus H1 2026 145.3p). On trailing twelve-month adjusted diluted earnings of roughly 368p the same price is about 11.1x, and the gap is almost entirely the swing in Canadian litigation accounting between periods.
P/E (forward)	~10.6x on a forward diluted EPS of about 387p, consistent with management's guidance of adjusted earnings-per-share growth in the middle of its 5–8% range for FY2026
P/S (TTM)	~3.4x (market cap £88.3bn / trailing twelve-month revenue of £25.78bn, being FY2025 £25,610m less H1 2025 £12,069m plus H1 2026 £12,235m)
EV/EBITDA (TTM)	~9.5x (enterprise value £119.5bn / EBITDA of £12.54bn). EBITDA here is FY2025 reported profit from operations of £9,997m plus £2,547m of depreciation, amortisation and impairment — the wider total from the SEC XBRL cash-flow add-back, not the narrower £2,245m of depreciation plus intangible amortisation alone. Reported operating profit is distorted by the Canadian settlement accounting; on adjusted profit from operations of £11,572m plus the same add-back, the multiple is about 8.5x.
P/FCF	~15.3x (market cap £88.3bn / free cash flow of £5.79bn; free cash flow = FY2025 operating cash flow £6,342m less capital expenditure £551m, both from the SEC XBRL cash flow statement). The company's own narrower measure, free cash flow before dividends, was £4,048m for FY2025 after interest and other items, which would put the multiple at about 21.8x.
Price/book	~1.91x (share price against total equity attributable to owners of £46,033m at 31 December 2025)
Dividend yield	~6.0% on the FY2025 dividend of 245.04p at a price of 4,100p
52-week high	5,368p
52-week low	3,677p
Short interest (% of float)	— not published for this period. The Financial Conduct Authority moved its short-selling register to anonymised aggregate disclosure only from 13 July 2026, so individual net short positions in UK-listed shares are no longer public. Verify at fca.org.uk/publication/data/short-positions-daily-update.xlsx
Days to cover	— not published for this period, for the same reason. Short-interest data exists for the BTI American Depositary Share line on the NYSE but covers a different security and float and is not comparable to the London ordinary shares.

7. What Are They Building

Vapour. Vuse remains the largest part of New Categories. Vuse Ultra, a premium connected device, has rolled out in Canada, Germany and France with further markets planned for the second half of 2026. The competitive problem is not another branded rival but unregulated disposables, which is why the company spends heavily on enforcement advocacy alongside product development.

Heated products. glo Hilo and Hilo Plus, along with Hyper Pro+, use a dual-heating design and have launched in Japan, Poland and Italy. Japan is the decisive market for heated tobacco globally and is where the category's share gains are most visible.

Modern oral. Velo Plus reached the number two position in the US modern oral category within a year of launch, and a national rollout of Velo Max was planned for the second half of 2026. Nicotine pouches are the fastest-growing smokeless format and carry combustible-like margins without combustion, which is why the company treats this as the most valuable of the three New Categories.

Cost and capital discipline. The Fit2Win programme targets roughly £700m of annualised savings by 2028 at a one-off cost of about £950m. Capital expenditure guidance for FY2026 is around £750m, with operating cash conversion guided above 95%.

Beyond nicotine. Btomorrow Ventures, the group's corporate venture capital arm, holds more than 30 investments. British American Tobacco also holds a 48.7% economic stake in Organigram, with voting capped at 30%, following Organigram's acquisition of Sanity Group in February 2026. Ryde functional wellness shots are on sale in the United States, Australia and Canada. The Omni platform is the company's published evidence base on tobacco harm reduction, aimed at regulators and investors rather than consumers.

8. Competitive Landscape

The global tobacco industry is an oligopoly of four listed players plus China National Tobacco, which is state-owned and does not compete internationally. Market capitalisations below were checked live on 12 September 2026.

Peer	Market cap (September 2026)	Key 2025 metric
Philip Morris International (PM)	US$297.8bn	Q2 2026 net revenue of US$11.2bn, up 10.4%, with smoke-free revenue up 14.2% to US$3.88bn. The clear leader in the transition, driven by IQOS and Zyn (Philip Morris Q2 2026 results)
Altria Group (MO)	US$115.2bn	Q2 2026 revenue of US$6.11bn, with full-year adjusted earnings-per-share guidance raised to US$5.61–5.72. Almost entirely a US business (Altria Q2 2026 results)
Japan Tobacco (2914.T)	¥11,994bn	FY2025 revenue of ¥3,467.7bn, up 13.4%, with adjusted operating profit up 24.9% to ¥927.5bn — the strongest top-line growth of the four (Japan Tobacco FY2025 results)
Imperial Brands (IMB.L)	£18.8bn	FY2025 next-generation product net revenue up 13.7%. The smallest of the four and the most explicitly focused on cash return rather than transition (Imperial Brands FY2025 results)

The comparison that matters is with Philip Morris. Both companies are trying to move to smokeless, but Philip Morris is markedly further along and is growing revenue at double digits while British American Tobacco's is flat. That difference is reflected in the multiples: Philip Morris trades at roughly 26x trailing earnings against British American Tobacco's 14.1x. Investors are paying a large premium for a transition that is visibly working versus one that is still in progress.

9. Leadership and Insider Activity

Tadeu Marroco has been Chief Executive since 2023. Dragos Constantinescu joined as Chief Financial Officer and an Executive Director on 1 September 2026, having previously been chief executive of Asahi Europe and International; Javed Iqbal had served as interim Chief Financial Officer before him. Luc Jobin has chaired the board since 2021. Karen Guerra became Senior Independent Director at the conclusion of the 2026 Annual General Meeting, replacing Holly Keller Koeppel.

The dealings below were disclosed through Director/PDMR Shareholding notifications during 2026. "PDMR" means a person discharging managerial responsibilities — a director or senior manager whose share dealings must be reported.

Name	Date	Type	Shares	Price	Value	Plan Type
Tadeu Marroco (Chief Executive)	25 Aug 2026	Purchase	250	£42.89	£10,723	Dividend reinvestment
Person closely associated with T. Marroco	25 Aug 2026	Purchase	250	£42.89	£10,723	Dividend reinvestment
Tadeu Marroco (Chief Executive)	17 Aug 2026	Acquisition	377	Data not available	Data not available	Share plan award
Tadeu Marroco (Chief Executive)	01 Jul 2026	Purchase	Data not available	£45.63	Data not available	Partnership Share Scheme

These are routine plan purchases rather than conviction buying, and they are small in absolute terms. No large discretionary director disposals were disclosed in the period reviewed. A complete audit would require a full pull of the company's Regulatory News Service archive; the rows above are those that could be verified individually.

10. Key Risks

• Regulation (Existential): proposed US menthol bans and nicotine-level caps, premarket tobacco product application outcomes, flavour restrictions and generational sales bans can each remove whole revenue lines. This is the dominant risk and it is not within the company's control in any market.
• Illicit trade (Commercial): unregulated disposable vapes and smuggled cigarettes pay no duty and follow no rules, so they undercut legal products on both price and availability. Australia, where illicit product is roughly 80% of combustible volume, shows how completely a legal market can be displaced.
• Structural volume decline (Operational): global cigarette volumes fell about 4.6% in H1 2026. Price increases have offset volume so far, but every year of decline narrows the base over which those increases can be taken.
• Material litigation (Legal): the Canadian settlement under the Companies' Creditors Arrangement Act is being paid down from Canadian net income, and three UK High Court shareholder claims over historical North Korea sanctions disclosure were filed between February and September 2026. Legal outcomes have repeatedly overwhelmed reported profit.
• Leverage (Financial): total borrowings were £35,070m at the end of FY2025 against equity of £46,033m, with adjusted net debt to adjusted EBITDA at 2.48x. The 2.0–2.5x target leaves limited room, and refinancing costs rise if credit ratings move.
• Currency translation (Financial): the group reports in sterling but earns most of its money elsewhere. Reported and constant-currency figures have diverged materially and unfavourably, and dividends are declared out of reported sterling earnings.
• Geopolitical exposure (Operational): the Pryluky manufacturing facility in the Chernihiv region of Ukraine was damaged in a Russian strike in early September 2026. The group operates in a number of politically unstable markets where assets and supply chains are at physical risk.
• Index and mandate exclusion (Capital markets): environmental, social and governance screens exclude tobacco from a growing pool of funds, structurally narrowing the buyer base regardless of the financial results.

11. Recent Developments

• 12 Feb 2026 — FY2025 preliminary results. Revenue of £25,610m, reported profit from operations of £9,997m, adjusted diluted earnings per share of 352.1p and a dividend of 245.04p, up 2.0%. A £1.3bn buyback for 2026 was confirmed and leverage fell to 2.48x.
• 28 Feb 2026 — Cuban joint venture exit completed. The sale of the group's 50% stake in Brascuba to Tabagest completed and the business was deconsolidated.
• 15 Apr 2026 — Annual General Meeting. Karen Guerra was appointed Senior Independent Director at the close of the meeting, replacing Holly Keller Koeppel.
• 11 May 2026 — US sanctions proceedings dismissed. The US Department of Justice moved to dismiss with prejudice the North Korea sanctions proceedings, confirming compliance with the 2023 deferred prosecution agreement.
• 30 Jul 2026 — H1 2026 results. Revenue of £12,235m, up 2.9% at constant currency, adjusted profit from operations of £5,426m and operating cash flow up 47.3% to £3,402m. Adjusted earnings-per-share growth guidance was raised to the middle of the 5–8% range and smokeless products reached 19.8% of revenue.
• 14 Aug 2026 — Second quarterly dividend paid. The second of four instalments of 61.26p per share reached shareholders.
• 01 Sep 2026 — New Chief Financial Officer took office. Dragos Constantinescu joined as Chief Financial Officer and Executive Director, ending the interim arrangement under Javed Iqbal.
• 07 Sep 2026 — Ukraine facility damaged. The Pryluky manufacturing plant in the Chernihiv region was damaged in a Russian strike; no injuries were reported.

12. Key Dates to Watch

• 01 Oct 2026 — shares commence trading ex-dividend on the London Stock Exchange for the third quarterly instalment of 61.26p (record date 2 October 2026)
• 06 Nov 2026 — payment date for the third quarterly dividend instalment on the London and Johannesburg registers; the American Depositary Share payment date is 12 November 2026
• Expected Dec 2026 — pre-close trading update, the next opportunity for management to revise FY2026 guidance
• 24 Dec 2026 — shares commence trading ex-dividend on the London Stock Exchange for the fourth quarterly instalment (record date 29 December 2026)
• 03 Feb 2027 — payment date for the fourth quarterly dividend instalment
• 11 Feb 2027 — FY2026 preliminary results, the next full earnings event; expect the FY2027 dividend declaration and the 2027 buyback decision alongside it
• Expected Apr 2027 — Annual General Meeting; the exact date has not yet been published

Scheduled macro and earnings events are listed on the ChartsView Economic Calendar, and discussion of consumer staples and dividend shares is in the ChartsView Forum.

---

Disclaimer: This research is produced by ChartsView for educational and informational purposes only. It does not constitute financial advice or a recommendation to buy or sell any security. All information is sourced from publicly available company filings, press releases, and official data. ChartsView does not use analyst opinions or third-party ratings. Always conduct your own due diligence and consider your personal financial situation before making investment decisions. Past performance is not indicative of future results.